BSTC BioSpecifics Technologies Corp

61.26
+1.26  (+2%)
Previous Close 60
Open 59.29
Price To Book 4.86
Market Cap 445858795
Shares 7,278,139
Volume 41,038
Short Ratio
Av. Daily Volume 36,332

SEC filingsSee all SEC filings

  1. 8-K - Current report 181196453
  2. 8-K - Current report 181190689
  3. 8-K - Current report 181173969
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181172199
  5. 8-K - Current report 181153152

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Endo is currently performing a commercial assessment.
XIAFLEX
Plantar fibromatosis
Phase 2 topline data released June 2016 - endpoints met
XIAFLEX
Human lipomas
Phase 3 data released November 7, 2018 - primary endpoint met.
XIAFLEX (collagenase clostridium histolyticum) - RELEASE
Edematous fibrosclerotic panniculopathy (“cellulite”)
Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.
XIAFLEX
Adhesive Capsulitis (“Frozen Shoulder syndrome”)
Phase 1 data released October 31, 2018 - primary endpoint of safety and tolerability met.
XIAFLEX
Uterine fibroids

Latest News

  1. Portola (PTLA) Down as CHMP Defers Review Date for Ondexxya
  2. Jazz (JAZZ) Increases Share Buyback Authorization by $400M
  3. Novan Announces Top-Line Data From Mid-Stage Molluscum Study
  4. Why Tilray (TLRY) Could Be Positioned for a Slump
  5. Should You Get Rid of Aerie Pharmaceuticals (AERI) Now?
  6. Theravance Pipeline Strong, Plans Yupelri Launch by Year End
  7. Theravance's Respiratory Disease JAK Inhibitor Enters Phase I
  8. Market Trends Toward New Normal in Amarin, BioSpecifics Technologies, Cavco Industries, Iconix Brand Group, A-Mark Precious Metals, and Core-Mark Holding — Emerging Consolidated Expectations, Analyst Ratings
  9. Is BioSpecifics Technologies Corp. (NASDAQ:BSTC) Worthy of Your Portfolio?
  10. Theravance JAK Inhibitor Enters Phase II for Crohn's Disease
  11. IntelGenx's NDA Resubmission for Rizaport Gets FDA Acceptance
  12. IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses
  13. Galmed Pharmaceuticals (GLMD) in Focus: Stock Moves 6.2% Higher
  14. TESARO (TSRO) Jumps: Stock Rises 5.4%
  15. BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development
  16. Managers Of This Fund Like The Outlook For Small-Cap Stocks
  17. Is BioSpecifics Technologies Corp (NASDAQ:BSTC) Excessively Paying Its CEO?
  18. BioSpecifics Technologies (BSTC) Q3 Earnings and Revenues Beat Estimates
  19. BioSpecifics: 3Q Earnings Snapshot
  20. BioSpecifics Technologies Corp. Reports Third Quarter 2018 Financial Results

SEC Filings

  1. 8-K - Current report 181196453
  2. 8-K - Current report 181190689
  3. 8-K - Current report 181173969
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181172199
  5. 8-K - Current report 181153152
  6. 8-K - Current report 181072013
  7. 8-K - Current report 181037290
  8. 8-K - Current report 181005093
  9. 10-Q - Quarterly report [Sections 13 or 15(d)] 181004385
  10. 8-K - Current report 18934756